Evidence map›Paper›PMID 41685666›Full record

ArticleIntegrative cancer therapies

Phase 1 Trial of

Jin Uk Heo, Santosh Rao, Herbert B Newton, Afshin Dowlati, Raymond F Muzic, Arash Kardan

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05580172 (A Phase 1 Open Label Dose Ranging Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05580172 phase1unknown statusnot on this map

A Phase 1 Open Label Dose Ranging Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

TypeinterventionalSponsorReHeva Biosciences,Inc.Ran2022 to 2025Enrolled6ConditionsSafety IssuesArmsRH324
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Plant Part-Specific Differences in Ashwagandha (Food science & nutrition · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jin Uk HeoDepartment of Radiology, Case Western Reserve University and University Hospitals Cleveland Medical Center, OH, USA.
Santosh RaoSeidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Herbert B NewtonSeidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Afshin DowlatiSeidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Raymond F MuzicDepartment of Radiology, Case Western Reserve University and University Hospitals Cleveland Medical Center, OH, USA.
Arash KardanDepartment of Radiology, Case Western Reserve University and University Hospitals Cleveland Medical Center, OH, USA.ORCID 0009-0009-0220-0296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsA phase 1 open label dose ranging study of oral RH324 in advanced non-small cell lung cancer (NSCLC) was conducted. The primary endpoint of the study was assessment of short-term safety and tolerability. An exploratory aim was assessment of RH324's anti-neoplastic effects as measured by changes in tumor metabolism using [

resultsAll study safety and tolerability primary endpoints were met. Analysis revealed notable response rates across different SUV parameters (SUV

conclusionRH324 was safe and well tolerated as a monotherapy in advanced NSCLC. FDG-PET/CT provided a novel methodology as a short-term metabolic endpoint with an in vivo biomarker assessment of potential clinical efficacy using a metabolic surrogate of disease activity. This approach offered deeper insights into tumor metabolism and heterogeneity, underscoring the potential of RH324's anti-neoplastic effects in treating refractory NSCLC. CLINICAL

trial registrationClinicalTrials.gov, Identifier: NCT05580172, Registered on October 17, 2022.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPlant ExtractsWithaniaAdultAgedBiomarkers, TumorFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPlant LeavesPositron Emission Tomography Computed TomographyBiomarkers, TumorFluorodeoxyglucose F18Plant ExtractsFDGintegrative oncologylung cancerphase 1 human trialpositron emission tomographyWithania somnifera

Identifiers

PMID41685666
PMCPMC12905094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.